Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62.9M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
28.1M
-
Shares change
-
+5.15M
-
Total reported value, excl. options
-
$93.1M
-
Value change
-
+$16.2M
-
Put/Call ratio
-
0.04
-
Number of buys
-
43
-
Number of sells
-
-35
-
Price
-
$3.31
Significant Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q2 2024
99 filings reported holding PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.1M shares
of 62.9M outstanding shares and own 44.68% of the company stock.
Largest 10 shareholders include Deep Track Capital, LP (4.18M shares), Laurion Capital Management LP (3.86M shares), BlackRock Inc. (2.79M shares), Balyasny Asset Management L.P. (2.56M shares), VANGUARD GROUP INC (2.06M shares), Ikarian Capital, LLC (1.66M shares), MILLENNIUM MANAGEMENT LLC (1.34M shares), STEMPOINT CAPITAL LP (1.2M shares), Blue Owl Capital Holdings LP (1.05M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.03M shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.